ClinicalTrials.gg
RecruitingNCT06369870PAINCAREUpdated Oct 28, 2026

Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy

A Phase 4 interventional study of Levobupivacaine Hydrochloride 0.25 % Injectable Solution and Sodium chloride 0.9% in Analgesic Effect, sponsored by Algemeen Ziekenhuis Maria Middelares. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Algemeen Ziekenhuis Maria Middelares · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the analgesic effect of locoregional anaesthesia, specifically the interpectoral pectoserratus plane (IPP-PSP) block, in comparison to a placebo (sham block) after Aortic Valve Replacement via Right Anterior Minithoracotomy (AVR-RAT). The main question the trial aims to answer is: Can the IPP-PSP block effectively reduce opioid consumption within the first 48 hours after AVR-RAT surgery? The purpose is to understand the impact of the IPP-PSP block on postoperative pain. Therefore, the aim is to investigate the influence of the IPP-PSP block on the amount of pain medication administered during the patients' first 48 hours after surgery.

Participants, who are scheduled for AVR-RAT surgery, will be randomly assigned to receive either the IPP-PSP block or the sham block. Researchers will compare opioid consumption among other outcomes, including differences in pain scores, incidence of nausea and vomiting, quality of recovery, quality of life, and the length of hospital stay between the two groups.

Patients will be monitored during their hospitalization, and a follow-up phone call will be conducted 30 days after surgery.

Read the detailed description

This clinical trial aims to evaluate the analgesic effect of an interpectoral-pectoserratus plane (IPP-PSP) block compared to a placebo (sham block) in patients undergoing aortic valve replacement via right anterior minithoracotomy (AVR-RAT). The primary objective is to determine whether the IPP-PSP block effectively reduces opioid consumption during the first 28 hours post-surgery.

The trial is designed as a single-center, prospective, double-blind, randomized controlled superiority trial. It will enroll adult patients aged 18 years or older who are scheduled for minimally invasive AVR-RAT and meet specific inclusion criteria. Exclusion criteria are established to ensure the safety and integrity of the trial.

Patients undergoing minimally invasive AVR-RAT will be randomly assigned to either the IPP-PSP block group or the sham block group.

The primary endpoint of the trial is the cumulative opioid consumption (in oral morphine milligram equivalents (OMEs)) within the first 48 postoperative hours after completion of the surgical procedure. Secondary outcomes include the number of episodes of postoperative pain, time to need for rescue medication, incidence of respiratory complications, PaCO2 levels, postsurgical recovery, episodes of postoperative nausea and vomiting, time to extubation in the Intensive Care Unit (ICU), ICU length of stay, hospital length of stay, quality of life, number of days alive and at home after surgery, and vital status at 30 days post-operative.

The trial aims to enroll a total of 144 patients, with 72 patients randomized into each group. Blinding will be implemented, meaning neither the participant, anesthesiologist, study nurse, surgeon, nor the doctors and nurses in the Intensive Care Unit will know the participant's group assignment.

The anesthesia and monitoring proceed as usual for such procedures. After the anesthesiologist administered the IPP-PSP block or a placebo at the end of the procedure, the participant will be transferred to the ICU. During the hospital stay, they will be regularly asked to assess their pain level, and additional pain relief will be administered, if necessary.

To assess quality of recovery and quality of life differences between groups, participants will complete two questionnaires the day before surgery. A recovery questionnaire will be completed at three time points post-surgery (day 1, day 2, and day 7 after the surgery). Participants will be involved in the trial for a total of 31 days, with follow-up during hospitalization and a follow-up phone call 30 days post-surgery.

02

Conditions studied

  • Analgesic Effect

Keywords

  • interpectoral-pectoserratus plane block
  • aortic valve replacement via right anterior minithoracotomy
  • IPP-PSP block
  • AVR-RAT
03

In context

Lead sponsor

Algemeen Ziekenhuis Maria Middelares is the lead sponsor of 37 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18 years of age or older);
  • Patients scheduled for minimally invasive aortic valve replacement via right anterior minithoracotomy;
  • Patients with (ASA) physical status classification II, III or IV;
  • Patients with European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2 ≤ 4%;
  • Patient has given written, free and .

Exclusion criteria

Exclusion Criteria:

  • > 35;
  • Patients under legal protection (curatorship, guardianship);
  • Patients subject to a legal protection measure;
  • An adult who is incapable or unable to give consent;
  • Patients requiring emergency surgery within 24 hours;
  • Chronic opioid use (> 3 administrations per week or continuous transdermal therapy, longer than the last 3 months);
  • Patients known with chronic pain;
  • Patients known with an allergy to levobupivacaine or drugs used as standard of care, including amongst others piritramide, dexamethasone, propofol, remifentanil, rocuronium, acetaminophen, ondansetron;
  • Patients who receive medication that could possibly interact with levobupivacaine (mexiletine, ketoconazole, theophylline);
  • Patients who took monoamine oxidase (MAO) inhibitors within the last 2 weeks before surgery;
  • Patients with chronic renal failure (dialysis dependent, estimated (eGFR) \< 30 ml.min-1.(1,73 m²)-1) ;
  • Patients with severe hepatic impairment (Model for End-Stage Liver Disease (MELD) score ≥ 20);
  • Patients with preoperative cognitive dysfunction ( (MMSE) score \< 24);
  • Patients with uncontrolled epilepsy;
  • Patients with severe arterial hypotension (Systolic Arterial Pressure (SAP) \< 90 mmHg, cardiogenic shock);
  • Patients who simultaneously participate in another interventional clinical trial;
  • Soft tissue infection in the area of the procedure;
  • Patients who are pregnant, parturient or breast-feeding women;
  • Patients who are unable to sufficiently speak and write in the Dutch language.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Levobupivacaine Hydrochloride 0.25 % Injectable Solution

    Unilateral (right) IPP-PSP block with 30 mL levobupivacaine 0.25%, administered after the closure of the wounds. After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).

    Drug: Levobupivacaine Hydrochloride 0.25 % Injectable Solution

  • Sham comparator
    Sodium chloride 0.9%

    Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the Active Comparator.

    Drug: Sodium chloride 0.9%

Interventions

  • DrugLevobupivacaineStudies of LevobupivacaineLevobupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).

    Also known as: IPP-PSP block, Intervention group

  • DrugSodium chloride 0.9%

    Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the intervention description of the IPP-PSP block.

    Also known as: Sham block, Control group

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption

    Cumulative opioid consumption (in oral morphine milligram equivalents (OMEs)) in the first 48 postoperative hours after the completion of the surgical procedure

    Time frame: in the first 48 hours after completion of the surgical procedure

Secondary outcomes

  1. Number of episodes of postoperative pain

    Number of episodes of postoperative pain (NRS score ≥ 4) at rest and at deep inspiration in the first 48 postoperative hours after the completion of the surgical procedure

    Time frame: In the first 48 hours after completion of the surgical procedure

  2. Time to need for rescue medication

    Time to need for rescue medication for breakthrough pain (e.g. tramadol, oxycodone) in the first 48 postoperative hours after the completion of the surgical procedure (minutes)

    Time frame: In the first 48 hours after completion of the surgical procedure

  3. Number of patients with respiratory complications

    Number of patients with respiratory complications, leading to non-invasive ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen therapy, orotracheal intubation for more than 24 hours or orotracheal re-intubation

    Time frame: During hospital stay (on average 7 days)

  4. PaCO2 levels

    Levels of arterial partial pressure of carbon dioxide (PaCO2) measured every 4 hours during the 48 postoperative hours after the completion of the surgical procedure or until Intensive Care Unit (ICU) discharge, whichever occurs first

    Time frame: During the 48 postoperative hours after the completion of the surgical procedure or until Intensive Care Unit (ICU) discharge, whichever occurs first;

  5. Postsurgical Quality of Recovery measured by the Quality of Recovery questionnaire

    Postsurgical recovery by Quality of Recovery questionnaire (QoR-15NL) on day before (D-1), first (D1), second (D2) and seventh (D7) day after surgery. The minimum score on the Quality of Recovery questionnaire is 0 and the maximum score 150. Higher scores mean better quality of recovery.

    Time frame: Day before, first, second and seventh day after surgery

  6. Number of episodes of postoperative nausea and vomiting

    Number of episodes of postoperative nausea and vomiting (PONV) in the first 48 postoperative hours after the completion of the surgical procedure: nausea yes/no, vomiting: yes/no

    Time frame: Number of episodes of postoperative nausea and vomiting (PONV) in the first 48 postoperative hours after the completion of the surgical procedure: nausea yes/no, vomiting: yes/no

  7. Time to extubation

    Time to extubation of the patient in the Intensive Care Unit

    Time frame: Minutes (assessed up to 6 hours after surgery)

  8. Number of hours spent in the Intensive Care Unit

    Number of hours spent in the Intensive Care Unit (until ready for discharge)

    Time frame: Hours (on average 48 hours)

  9. Hospitalization duration

    Number of days in the hospital between surgery and first hospital discharge

    Time frame: Days (on average 7 days)

  10. Quality of life measured by the 5 level version of the EuroQoL-5 Dimension questionnaire

    The quality of life by the EQ-5D-5L questionnaire on the day before surgery and 30 days (D30) after surgery. The minimum health utility value of the Belgian EQ-5D-5L value set is -0.532 and the maximum value 1 in Belgium. Higher utility scores mean better health related quality of life.

    Time frame: Day before and 30 days after surgery

  11. Days alive and at home

    Number of days alive and at home after surgery (DAH30)

    Time frame: 30 (+7) days after surgery

  12. Vital status (whether the patient is alive or dead)

    Vital status at 30 days after surgery

    Time frame: 30 (+7) days after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Feb 2028, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Nov 2027 → Feb 2028 and completion Dec 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 17, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Feb 2028was Nov 2027
CompletionEst.
Mar 2028was Dec 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2027→Feb 2028
Oct 28, 2026
Study completion
Dec 2027→Mar 2028
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • AZ Maria Middelares · Ghent, BelgiumContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Nov 2027→Feb 2028
    Study completion Dec 2027→Mar 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • AZ Maria Middelares · Ghent, BelgiumContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06369870
Lead sponsor
Algemeen Ziekenhuis Maria Middelares
Responsible party
Bart Vaes, MD (Principal Investigator, Algemeen Ziekenhuis Maria Middelares) — Principal investigator
First posted
Apr 17, 2024
Start date
Sep 1, 2024
Primary completion
Feb 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Bart Vaes, MD
Contact
bart.vaes@mijnziekenhuis.be
0032 9 246 17 00
Ella Hermie, MSc
Contact
ella.hermie@mijnziekenhuis.be
0032 9 246 17 03
Bart Vaes, MD
principal investigator · Algemeen Ziekenhuis Maria Middelares

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levobupivacaine

Start the discussion